35th ESMO Congress

35th ESMO Congress

08 - 12 October, 2010
Milan, Italy

  1. Access to novel drugs improves survival
  2. Active surveillance in early prognosis prostate cancer should be standard of care
  3. Advances in head and neck cancer
  4. Advances in neuroendocrine tumors
  5. Advances in systemic treatment of metastatic melanoma
  6. Advances in the treatment of advanced colorectal cancer
  7. Advances in the treatment of metastatic or unresectable biliary tract cancer
  8. Anti-angiogenic agents should be used for the first-line treatment of ovarian cancer
  9. Approaches to adjuvant treatment of small tumors
  10. Awards session
  11. Basic science and translational research
  12. Basic science and translational research
  13. Biomarkers
  14. Biomarkers I
  15. Biomarkers II - Circulating tumor cells and molecular markers
  16. Breakout session: Latest developments in breast cancer
  17. Breakout session: Latest developments in gastrointestinal tumors
  18. Breakout session: Latest developments in hematological malignancies
  19. Breakout session: Latest developments in prostate cancer
  20. Breast cancer challenges in the setting of curable disease
  21. Breast cancer, advanced
  22. Breast cancer, advanced
  23. Breast cancer, early
  24. Bristol-Myers Squibb: Recent advances in immunotherapy for advanced melanoma
  25. Bullseye: PARP
  26. Cancer of unknown primary site (CUP): 20 questions to be answered
  27. Cancer: We all care and share
  28. Challenging cases in testicular cancer
  29. Challenging issues in ovarian cancer
  30. Chest tumors
  31. Chest tumors II
  32. Chronic Disease Alliance: A time to work across specialties
  33. Colorectal cancer
  34. Colorectal cancer
  35. Communication skills training (CST)
  36. Congress Highlights
  37. Detection, clinical relevance and specific biological properties of disseminated cancer cells
  38. Developmental therapeutics
  39. Developmental therapeutics
  40. Diagnostic and management issues in gastroesophageal cancer
  41. Diagnostic and management issues in metastatic breast cancer
  42. Do we always need specific cancer treatment?
  43. Early endometrial cancer
  44. Early-stage NSCLC: Challenges in staging and adjuvant treatment
  45. Emerging concepts in head and neck cancer diagnostics and therapy
  46. ESMO Clinical Practice Guidelines
  47. ESMO DCTF/UICC/WHO Joint Symposium: Meeting the challenge of managing cervical cancer in the developing world
  48. ESMO/AIOM Joint Symposium: Young medical oncologists facing daily difficulties in clinical practice
  49. ESMO/ASCO Joint Symposium: The future of antiangiogenesis therapy
  50. ESMO/CSCO Joint Symposium. Personalised medicine: Do ethnic differences matter?
  51. ESMO/ESTRO/ESSO Joint Symposium. Surgery, radiotherapy and ablation of metastatic disease and chemotherapy for localized disease: Changing roles in multidisciplinary management of colorectal cancer
  52. ESMO/JSMO Joint Symposium. Biomarkers and selected therapeutics in lung and GI cancer
  53. ESMO/OECI Joint Symposium. The more (we are), the better (we serve)! ESMO and OECI: towards high-quality cancer care
  54. European Union Translational Research Program
  55. Genetic counselling for hereditary predisposition to ovarian and breast cancer
  56. Genitourinary tumors
  57. Genotyping GIST for clinical decision-making
  58. Geriatric oncology
  59. Gynecological cancer
  60. Gynecological cancer
  61. Head and neck cancer
  62. Head and neck cancer
  63. Hematological malignancies
  64. Hepatocellular carcinoma: A multi-step therapeutic approach
  65. How much do we know about cancer cells?
  66. How to improve curability of locally advanced head and neck cancer
  67. Janssen-Cilag: New treatment options for patients with relapsed ovarian cancer or advanced prostate cancer
  68. Late-Breaking Abstract Session
  69. Living with cancer: Early rehabilitation
  70. Living with cancer: Long-term rehabilitation
  71. Locally advanced laryngeal cancer
  72. Locally advanced pancreatic cancer
  73. Locally advanced rectal cancer
  74. Maintenance treatment of advanced NSCLC: Utopia or necessity?
  75. Melanoma
  76. MicroRNA’s: The new genes involved in cancer
  77. Nasopharyngeal cancer
  78. New therapeutic opportunities in urological cancer
  79. Oncology Mentors Forum
  80. Opening Ceremony
  81. Optimal integration of chemotherapy and radiotherapy in small cell lung cancer
  82. Ovarian cancer: New biology, new targets
  83. Overcoming disparities in cancer control in Europe
  84. Over-diagnosis of breast cancer by screening is a peril
  85. Patient Seminar Opening session and Welcome
  86. Presidential Symposium
  87. Prevention and treatment of side effects of systemic treatment
  88. Review and general discussion
  89. Sarcoma
  90. Soft tissue sarcoma: From molecular diagnosis to selection of treatment
  91. Supportive and palliative care
  92. Supportive and Palliative Care
  93. Tailoring treatment of metastatic colorectal cancer
  94. Targeted agents in prostate cancer: Changing the paradigms
  95. Targeted therapies in NSCLC: State-of-the-art and new developments
  96. Targeting molecular pathways in the jungle of soft tissue sarcoma histology
  97. Team work in palliative care
  98. The use of biomarkers to guide treatment in hematological malignancies
  99. Towards an individualized approach of advanced non-small cell lung cancer
  100. Toxicities of targeted therapies: Prevention and management
  101. Treatment of PT1N0 breast cancer
  102. Understanding new methods and new treatments of cancer
  103. Updates in B-cell malignancies
  104. Upper gastrointestinal tumors
  105. Upper gastrointestinal tumors
  106. Young Oncologist Masterclass: The importance of conducting well-designed clinical trials
  107. Young Oncologists Breakfast: How to write an outstanding manuscript
  108. Young Oncologists Breakfast: Medical information: Where to find it, what to trust

Search within Webcasts

 
 

 

 
 
 
 
 
 

Spotlight

ESMO Guidelines: How deep we go in personalized medicine

Session: Guidelines

Congress: Personalized medicine 2013 - Signalling Pathways

01 - 02 March, 2013; Sitges, Spain

Most Viewed Webcasts